This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The package crafted by Senate Finance Chair Ron Wyden (D-Ore.) The pharmacy benefit manager regulations build on a separate package of PBM regulations that the panel passed in July. and Mike Crapo (R-Idaho) is slated to be marked up on Nov.
WASHINGTON – The Senate health committee on Thursday passed a package of bills aimed at speeding generic drug competition and reining in drug middlemen business practices. is pursuing the drugpricing reforms at the behest of Senate Majority Leader Chuck Schumer (D-N.Y.), Chairman Bernie Sanders (I-Vt.)
8 on legislation that includes substance abuse and mental health policies, reforms to drug middlemen’s business practices, and extensions to provider payment policies in Medicare and Medicaid, according to five health care lobbyists. WASHINGTON — The Senate Finance Committee plans to vote Nov. Read the rest…
At a time when many Americans are clamoring for more transparency into prescription drugpricing, one key provider of that data is making it harder to access the information. This includes details such as separate doses and packaging on both current and historical prices. Continue to STAT+ to read the full story…
WASHINGTON — Generic drugmakers lobbied hard against Democrats’ new law empowering Medicare to negotiate prescription drugprices. Now that the changes are law, however, industry experts and lobbyists acknowledge the package is more of a mixed bag for generics makers like Teva and Sandoz, not an existential threat.
They’re focused this summer on reining in pharmacy middlemen to make the system fairer — but none of their many proposals will actually tackle the core dynamic that has incentivized higher drugprices. There are major packages on so-called PBM reform percolating in at least six different congressional committees.
The ins and outs of the new House health package House Republicans on three panels circulated a draft health price transparency package with some reforms to payment practices of PBMs and hospitals, I reported yesterday. Sign up here to receive this newsletter in your inbox on Tuesdays and Thursdays.
WASHINGTON — One of Washington’s most prominent drugpricing patient groups is tapping an advocate who has fought for access to medicines for nearly two decades as its new leader. Continue to STAT+ to read the full story…
… Novo Nordisk has hired PCI Pharma Services, a contract manufacturer, to handle assembly and packaging of Wegovy as it races to boost output of the weight-loss drug to meet demand , Reuters reports. Meanwhile, here are some tidbits to help you along. Hope you have a smashing day, and do stay in touch. Attorneys for the U.S.
WASHINGTON — A prominent Senate panel on Wednesday passed a new package of health policy reforms that would rein in certain pharmacy middlemen practices and ensure Medicare patients aren’t paying more than insurers do for medications. The package passed the committee 26-0 with no amendments added. Ron Johnson (R-Wis.)
That lame duck period might be an opportune time for Congress to pass a health care legislative package that includes PBM reforms, though it’s difficult to predict what will happen following the elections. Continue to STAT+ to read the full story…
billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition would give the pharmaceutical company an unfair advantage in the burgeoning market for drugs used to treat obesity and diabetes.
WASHINGTON — Congress will not move forward with a controversial policy to equalize certain Medicare payments to hospitals and physicians’ offices in an upcoming government funding package, five lobbyists and sources following the talks told STAT. The delay is a win for hospitals, which have adamantly lobbied against the policy.
About last night… House leadership last night canceled a scheduled vote on a health care package that included transparency requirements for hospitals and insurers, reforms to some PBM practices, and a small site-neutral payment policy for administering drugs, Rachel writes.
The lawsuit was filed in response to a state law that was passed in August and requires health insurers that provide coverage for these injectors to cap out-of-pocket costs to $60 for a package of two injectors. At the same time, the law — which goes into effect Jan.
Eli Lilly, a chief Novo rival, uses Catalent for filling and packaging, and has complained openly about the deal. Continue to STAT+ to read the full story…
Simply put, a drug company combines two or more medicines in a package deal for health plans and pharmacy benefit managers, which determine lists of medicines that are covered by insurance. Regulators were concerned about a practice known as bundling.
The House Ways & Means Committee package includes a new provision that would ensure that patients in the Medicare program pay for medicines they pick up at the pharmacy counter based on the discounted price that insurers negotiate with drugmakers, instead of higher sticker prices, starting in 2027.
The company had said in April it would pause or discontinue at least four studies of experimental drugs to focus on more lucrative options including the Leqembi launch and trim costs.
6 would prevent the HHS Secretary from requiring a switching study as part of the data package to receive the interchangeable designation. Pitts: The IRA makes the risks of developing new drugs too high On September 14th, an op-ed by former FDA Associate Commissioner Peter J. However, S.6 ASBM surveys of U.S.
One reason at play is the concern that the Japanese pharmaceutical industry has shown about the impact of annual price revisions. This trend continues as it estimated that the FY2022 price revision led to an average price reduction of 4% to 5% for major drug makers.
The most recen t of the webinars, hosted July 29th, examined the negative impact of the Inflation Reducation Act’s Medicare drugprice setting provisions. The guidance removed the interchangeability statement from the product label/package insert of interchangeable biosimilars.
The Importance of Generic Drugs in Healthcare Generic drugs offer several benefits to patients and the healthcare system: Cost-effectiveness: Generic drugs are typically much cheaper than brand-name medications, making treatment more accessible to patients.
REMINDER: FDA Draft Guidance Would Remove Interchangeability Statement from Interchangeable Biosimilars Comments Due November 17th On September 15th, the Food and Drug Administration (FDA) released draft guidance removing the interchangeability statement from the product label/package insert. ASBM surveys of U.S. However, S.6
One reason at play is the concern that the Japanese pharmaceutical industry has shown about the impact of annual price revisions. This trend continues as it estimated that the FY2022 price revision led to an average price reduction of 4% to 5% for major drug makers.
Consequentially, the five-year average price trend in Lebanon for all medicines has increased to 1,123%. GlobalData reviews the key events leading up to these current price trends in Lebanon. As this reduction of subsidies coincided with the weakening of the Lebanese pound, it resulted in further heavy price increases.
That’s why helping health systems minimize data mismatches at the source is so critical to maximizing 340B savings 340B drugpricing program savings for a covered entity — and why meeting that challenge is a core component of our 340B software and service package.
The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drugpricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. It is too early to say because we have not seen the whole package of measures yet.
Drug rebates can distort true drugpricing A small but growing number of employers see rebates as a pricing distortion. When medication volume is incentivized by the drug manufacturer, how motivated will the PBM be to stop wasteful use of drugs?
The drug-pricing plan was negotiated with Senator Joe Manchin III of West Virginia, but Democrats remain short of agreement on what else would be included in any domestic policy package.
Two potential 340B developments for 2024 In an article dated January 5, the subscriber-only website 340B Report projected that “In 2024, congressional gridlock and election year dynamics will likely slow momentum on any comprehensive 340B program reform package.”
Only two provisions in a once-sprawling social spending package have survived; they would lower prescription drugprices in Medicare and insurance premiums for millions of Americans.
An example is NICE’s Quality Adjusted Life Year score, used to pricedrugs in the UK. Some nations such as France base their decisions on the drug’s medical benefit and clinical added value versus existing therapies. Overall, it is never too soon to begin market access activities, but it can easily be too late.
This integrated approach keeps everything together in one package that is coordinated by your primary medical health plan vendor. For example, members can compare drugprices at pharmacies or find a network provider. What does it mean to carve in pharmacy? Why should employers care about transparency in pharmacy benefits?
Two potential 340B developments for 2024 In an article dated January 5, the subscriber-only website 340B Report projected that “In 2024, congressional gridlock and election year dynamics will likely slow momentum on any comprehensive 340B program reform package.”
And lawmakers are always eager to brag to voters that they took action against high prescription drugprices. CVS Caremark, Express Scripts, and Optum Rx face new transparency rules and restrictions on how they make money under a legislative package. Continue to STAT+ to read the full story…
The plan would give the administration authority to negotiate what price the federal government pays for more drugs than the limited number approved as part of Democrats’ legislative package last year, while also speeding up the process for negotiations.
WASHINGTON — The White House is pitching an added benefit to Democrats’ recent drugpricing reform package: lower cancer death rates. Over 449,000 current Medicare enrollees with a prior cancer diagnosis would save an average of nearly $1,600 per year on prescription drugs because of the out-of-pocket cap.
Appropriations The most pressing deadline facing Congress as they return from August recess is passing a federal spending package. This bill aims to delink the compensation of PBMs from drugprices. Below is a summary of key items to keep a lookout for in the coming months.
Advanced inducible systems to better regulate the expression of certain genes will improve the generation of packaging and producer cell clones, giving companies more control over gene expression for improved safety as well as efficiency. million for Hemgenix [AAV5-hFIX-Padua]).
In response, a debt ceiling package was signed without Medicaid work requirements, symbolizing the power of patient advocates’ voices. In submitted comments , the NHC commended CMS for its initiatives to reduce patient burdens, while also emphasizing the importance of continued monitoring and oversight to strengthen the program.
Over 150 House Democrats are pushing the president to include a plan in his infrastructure package to lower the eligibility age, expand benefits and negotiate drugprices.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content